James E. Fickenscher
2021 - Zynerba Pharmaceuticals
In 2021, James E. Fickenscher earned a total compensation of $1.2M as CFO and VP, Corporate Development at Zynerba Pharmaceuticals, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $175,127 |
|---|---|
| Option Awards | $215,145 |
| Salary | $422,230 |
| Stock Awards | $372,320 |
| Other | $10,663 |
| Total | $1,195,485 |
Fickenscher received $422.2K in salary, accounting for 35% of the total pay in 2021.
Fickenscher also received $175.1K in non-equity incentive plan, $215.1K in option awards, $372.3K in stock awards and $10.7K in other compensation.
Rankings
In 2021, James E. Fickenscher's compensation ranked 8,129th out of 12,415 executives tracked by ExecPay. In other words, Fickenscher earned more than 34.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,129 out of 12,415 | 35th |
Division Manufacturing | 3,594 out of 5,505 | 35th |
Major group Chemicals And Allied Products | 1,597 out of 2,375 | 33rd |
Industry group Drugs | 1,421 out of 2,096 | 32nd |
Industry Pharmaceutical Preparations | 1,056 out of 1,546 | 32nd |
Source: SEC filing on April 25, 2022.
Fickenscher's colleagues
We found two more compensation records of executives who worked with James E. Fickenscher at Zynerba Pharmaceuticals in 2021.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019